Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial-Reference-Cited by-同舟云学术

Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial

Published:2018-10-10 Issue:12 Volume:20 Page:2885-2893
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Buse John B.¹^ORCID,Carlson Anders L.²,Komatsu Mitsuhisa³,Mosenzon Ofri⁴,Rose Ludger⁵,Liang Bo⁶,Buchholtz Kristine⁶,Horio Hiroshi⁷,Kadowaki Takashi⁸

Affiliation:

1. Division of Endocrinology, Department of Medicine, University of North Carolina School of Medicine; North Carolina

2. International Diabetes Center; Minneapolis Minnesota

3. Division of Diabetes, Endocrinology and Metabolism, Department of Internal Medicine; Shinshu University School of Medicine; Nagano Japan

4. Diabetes Unit, Division of Internal Medicine; Hadassah Hebrew University Hospital; Jerusalem Israel

5. Institute of Diabetes Research; Münster Germany

6. Novo Nordisk A/S; Søborg Denmark

7. Novo Nordisk Pharma Ltd; Tokyo Japan

8. Department of Diabetes and Metabolic Diseases, Graduate School of Medicine; The University of Tokyo; Tokyo Japan

Funder

Novo Nordisk

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.13545/fullpdf

Reference23 articles.

1. Long-term complications of diabetes mellitus;Nathan;N Engl J Med,1993

2. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes;Nathan;N Engl J Med,2005

3. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview;Nathan;Diabetes Care,2014

4. 6. Glycemic targets: standards of medical care in diabetes-2018;American Diabetes Association;Diabetes Care,2018

5. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD);Ryden;Eur Heart J,2013

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ultrafast-acting insulin: pharmacological properties and their impact on clinical aspects;Meditsinskiy sovet = Medical Council;2024-09-02

2. New advances in type 1 diabetes;BMJ;2024-01-26

3. Ultrarapid Insulin Use Can Reduce Postprandial Hyperglycemia and Late Hypoglycemia, Even in Delayed Insulin Injections: A Connected Insulin Cap-Based Real-World Study;Diabetes Technology & Therapeutics;2024-01-01

4. The Role of Ultra-Rapid-Acting Insulin Analogs in Diabetes: An Expert Consensus;Journal of Diabetes Science and Technology;2023-11-08

5. Faster-acting insulin aspart versus insulin aspart in the treatment of type 1 or type 2 diabetes during pregnancy and post-delivery (CopenFast): an open-label, single-centre, randomised controlled trial;The Lancet Diabetes & Endocrinology;2023-11